Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
Browsing: Basic > Pre-clinical Trials
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
Learn more about the top news stories of the week in our round-up, including new guidance for drug-resistant infections and a Phase I trials for a MERS treatment.
Researchers have developed a drug delivery system that could allow antiretroviral drugs for HIV to be administered only once a week, potentially making it easier for patients to adhere to drug regimens.
MedChemNet and Infectious Diseases Hub recently attended the first two days of the 19th RSC / SCI Medicinal Chemistry Symposium. Here, you can catch up on the session delving into drug discovery for the neglected tropical diseases.
Researchers have discovered that antibodies taken from dengue virus infected individuals are effective in treating Zika infection – a closely related flavivirus – in rodents.
A novel trispecific antibody has been developed by researchers from the NIH and Sanofi, demonstrating effectiveness against of 99% of HIV strains and protective immunity in non-human primates.
Research in mice and cell lines has demonstrated the potential of Zika virus to target and kill glioblastoma stem cells, suggesting a possible new treatment for this brain cancer.
Improved therapeutic strategies are in urgent need for better control and eradication of tuberculosis. In this editorial, the authors evaluate interleukin-37 as a new molecular target for the therapy of tuberculosis.
Researchers have demonstrated an imaging technique utilizing PET, which allows non-invasive and real-time monitoring of dengue infection in mouse models.